Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06792695 · ClinicalTrials.gov registry record · Phase 2
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
A Phase 2 study of Metastatic Colorectal Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT06792695 is a Phase 2 study of Metastatic Colorectal Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 120 participants, below the 183-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (34% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT06792695, a Phase 2 study of Metastatic Colorectal Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Volrustomig
- DRUG FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)
Study Locations (20)
Other
- Research Site - East Melbourne
- Research Site - Wollongong
- Research Site - Woodville South
Ontario
- Research Site - Barrie
- Research Site - Toronto
Arizona
- Research Site - Scottsdale
California
- Research Site - Los Angeles
District of Columbia
- Research Site - Washington D.C.
Illinois
- Research Site - Chicago
Maryland
- Research Site - Baltimore
Massachusetts
- Research Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-03-12 |
| Est. Completion | 2028-06-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06792695
The ClinicalTrials.gov registry entry for NCT06792695 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 183-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (34% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT06792695 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Other, Ontario, Arizona.
Frequently Asked Questions
What is clinical trial NCT06792695 about?
NCT06792695 is a clinical study titled "A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer". The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
What is the current status of trial NCT06792695?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2025-03-12. Estimated completion is 2028-06-07.
What conditions does trial NCT06792695 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer.
What interventions are being tested in trial NCT06792695?
The interventions under investigation include: Bevacizumab (DRUG), Volrustomig (DRUG), FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan) (DRUG).
Who is sponsoring clinical trial NCT06792695?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06792695 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RECRUITING · Phase 2
-
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
RECRUITING · Phase 2
-
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
RECRUITING · Phase 2
-
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.